Nutriband Advances Abuse-Deterrent Fentanyl Patch with USPTO Trademark Publication — Nutriband Inc.

Event summary

Nutriband received a Notice of Publication from the USPTO for commercial brand name trademarks for its abuse-deterrent fentanyl transdermal system on September 2, 2026.
The trademarks will be published in the USPTO Trademark Official Gazette, with a 30-day opposition period before a potential Notice of Allowance.
Nutriband plans to submit its commercial brand name to the FDA and other international regulatory agencies for approval.
The abuse-deterrent fentanyl patch is based on Nutriband's AVERSA™ technology, with potential peak annual US sales of $80 million to $200 million.
AVERSA™ technology is protected by patents in 46 countries, including the US, Europe, Japan, and China.

The big picture

Nutriband's advancement in securing trademarks for its abuse-deterrent fentanyl patch marks a critical step in its regulatory pathway. The company's AVERSA™ technology addresses a significant unmet need in pain management, particularly in deterring opioid abuse. With a robust international patent portfolio, Nutriband is positioning itself to capitalize on the global demand for safer transdermal drug delivery systems. The potential market opportunity underscores the strategic importance of this development in the pharmaceutical industry.

What we're watching

Regulatory Approval: Whether the FDA and other international regulatory agencies will approve the commercial brand name and product labeling for Nutriband's abuse-deterrent fentanyl patch.
Market Potential: The pace at which Nutriband can capture the estimated $80 million to $200 million annual US market for its abuse-deterrent fentanyl patch.
Technology Expansion: How Nutriband will leverage its AVERSA™ technology in other transdermal patches to prevent abuse, misuse, and accidental exposure of drugs with abuse potential.